| Similar Articles |
|---|
 |
The Motley Fool
May 6, 2009
Robert Steyer |
Getting Ahead by Getting Rid of Wrinkles Medicis gets the FDA OK for an anti-wrinkle product as the market for Botox and other cosmetic skin drugs sags.   |
The Motley Fool
September 12, 2008
Brian Lawler |
A New Wrinkle for an Old Drug Allergan's muscle relaxant Botox performs well in two studies testing its ability to prevent migraine headaches. |
The Motley Fool
January 31, 2007
Brian Lawler |
No Earnings Face-Lift Needed For Allergan The ophthalmic and plastic surgery product developer has made many investors rich, and it's not stopping now. |
The Motley Fool
November 22, 2006
Brian Lawler |
Implant Approval Gives Allergan a Lift The return of silicone breast implants continues. Shares of Allergan, best known for its Botox wrinkle treatment, were up nearly 8% on the news. |
Chemistry World
June 10, 2008
James Mitchell Crow |
A Drug for Longer Lashes? US drugmaker Allergan, the California-based company that makes antiwrinkle treatment Botox, has developed a new cosmetic drug that makes eyelashes grow longer, thicker and darker. |
CRM
February 2003
David Myron |
Support Gets a Face-Lift Allergan was able to automate the routing of 80 percent of all inbound, Web-generated emails, based on the business rules the company put in place. |
The Motley Fool
August 23, 2010
Brian Orelli |
No Way to Jazz Up This Result Jazz Pharmaceuticals investors went from ecstatic to devastated in less than a week. |
The Motley Fool
June 29, 2009
Brian Orelli |
REMS: Not Just for Sleeping Anymore Risk Evaluation and Mitigation Strategies is saving drugmakers from going into a deep sleep while they wait for Food and Drug Administration approval of their drugs. |
The Motley Fool
June 5, 2008
Brian Lawler |
Allergan Lashes Out The pharmaceutical announces a new drug that could promote eyelash growth. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
BusinessWeek
October 13, 2003
Arlene Weintraub |
He Bet on Botox -- And Won David Pyott transformed sleepy Allergan. Where is he taking its blockbuster drug? |
BusinessWeek
December 25, 2006
Palmeri & Weintraub |
Silicone Goes Subtle Allergan's campaign relies on friendly persuasion. |
Chemistry World
April 29, 2014
Phillip Broadwith |
Valeant launches hostile bid for Allergan US drugmaker Valeant has lined up its next takeover target: Botox provider Allergan. Valeant has taken its proposal direct to shareholders, but Allergan has activated a 'poison pill' defense to buy time. |
The Motley Fool
December 15, 2003
Alyce Lomax |
No Wrinkles for Medicis Medicis Pharmaceuticals announced that the FDA has approved its injectable wrinkle-filling gel, Restylane. Allergan's Botox has found a new competitor in the fountain-of-youth market. |
The Motley Fool
September 20, 2007
Brian Lawler |
Allergan's Overactive Acquisition Specialty pharma Allergan announced yesterday that it is acquiring privately held Esprit Pharma for $370 million in an all-cash transaction. Investors, take note. |
The Motley Fool
February 18, 2010
Brian Orelli |
Still Restless for an Approval The FDA is like a box of chocolates: You never know what you're going to get -- rejection or acceptance. |
Chemistry World
June 24, 2015
Matthew Gunther |
Allergan to buy out Kythera Biopharma for $2.1bn The pharma firm Allergan will acquire Kythera Biopharmaceuticals in a $2.1 billion deal. |
The Motley Fool
January 15, 2009
Robert Steyer |
Medicis Tries to Save Face The wrinkle-removal drugmaker hopes it can smooth out a tough economy. |
The Motley Fool
December 16, 2005
Stephen D. Simpson |
A Romantic Rectangle in Health Care First Medicis wants Inamed, then Allergan wants Inamed. Now Mentor wants Medicis. Strange days in health care, to be sure. Investors, take note. |
The Motley Fool
March 4, 2010
Brian Orelli |
A Painless Drug Deal Bristol-Myers licenses pain drug from Allergan. |
The Motley Fool
August 8, 2006
Stephen D. Simpson |
Waiting on Fine Figures From Mentor Flush with cash, medical aesthetics specialist Mentor needs to reinvest in growth. This is a fine company that rarely trades cheap -- investors, take note. |
The Motley Fool
March 2, 2011
Susmita Chatterjee |
How to Capitalize on the Obesity Epidemic Does broader use of Allergan's Lap-Band signify competition for others? |
The Motley Fool
October 7, 2009
Jim Mueller |
Daily Walk of Shame: Money-Hungry Drugmakers If Allergan wins its suit against the government, consumers will really be in trouble. |
The Motley Fool
December 29, 2008
Brian Orelli |
Thicker Lashes, Fatter Wallets The Food and Drug Administration approves Allergan's Latisse, a treatment for sparse eyelashes. |
The Motley Fool
September 25, 2008
Brian Orelli |
Medicis Restates, Investors Panic Medicis says it'll have to restate earnings. |
BusinessWeek
March 25, 2010
Elizabeth Lopatto |
And Now, Gastric Surgery for Kids Allergan wants to market its Lap-Band implants for younger obese patients, but some doctors are balking |
CIO
December 14, 2010
Kim S. Nash |
How Botox Battles Compliance Wrinkles A BPM overhaul saved the day after legal issues complicated compliance at Botox-maker Allergan. |
Chemistry World
January 25, 2013
Andrew Turley |
Allergan buys MAP for $958m Allergan, best known as the company behind Botox (onabotulinumtoxin A) injections, has agreed to buy US drug maker MAP Pharmaceuticals for $958 million |
The Motley Fool
January 2, 2004
Dave Marino-Nachison |
Medicis: Skin Is In The drug maker has a strong balance sheet and a commitment to product development. |
The Motley Fool
May 19, 2006
Jim Mueller |
Foolish Forecast: Mentor's Uncertain Results Factors outside of the cosmetic surgery products maker's control are leading to short-term uncertainty. Investors, take note. |
The Motley Fool
June 10, 2008
Brian Lawler |
Allergan's Unblemished Deal Acquiring a niche acne drug from QLT provides clarity for both companies. |
The Motley Fool
June 17, 2008
Brian Orelli |
Acadia Gets Halved Acadia Pharmaceuticals loses half of the drugs in its clinical pipeline and half of its value in one day. |
The Motley Fool
April 13, 2009
Brian Orelli |
Will These Drugs Get Past the FDA? Hopefully April won't bring showers of tears to these drugmakers: Eli Lilly... AstraZeneca... Bristol-Myers Squibb... Novo Nordisk... Johnson & Johnson... |
Pharmaceutical Executive
July 1, 2009
Jill Wechsler |
Safety and Security As FDA looks to balance risks and benefits, more regulations are on the horizon. |
The Motley Fool
February 8, 2011
Esterhuizen & Sellitti |
Battle of the Bulge: Biotech Takes on Obesity and Diabetes Will recent advances in pharmaceutical research revolutionize the weight loss industry? It's still early days, but here are some of the stocks to watch. |
Chemistry World
July 3, 2015
Phillip Broadwith |
Job cuts at Allergan and Transgene Biotech firms Allergan and Transgene are both shuttering manufacturing facilities and laying off hundreds of staff. |
The Motley Fool
November 17, 2008
Brian Orelli |
Beauty Can Be a Beast Pinched pocketbooks are likely to hurt cosmetic-pharmaceutical companies more than any FDA warning. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
The Motley Fool
April 6, 2011
Brian Orelli |
Merck Inspired to Eye Growth A bolt-on acquisition of eye-care specialist Inspire. |
Chemistry World
November 27, 2015
Anthony King |
Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes. |
The Motley Fool
December 1, 2008
Brian Orelli |
Johnson & Johnson Firms Things Up The health-care giant acquires breast-implant maker Mentor. |
